top of page
tokers-guide-find-the-best-weed-in-dc-lo
NEW 1 to 1 photo editing 122024 (17).png
Rep. Alexandria Ocasio-Cortez criticized the U.S. drug scheduling system during a House subcommittee hearing, arguing that classifying substances like marijuana and LSD as Schedule I hinders medical research and fails to prevent overdose deaths. Expert witness Nabarun Dasgupta supported her claims, noting that these drugs have proven clinical benefits and that criminal penalties can lead to the emergence of more dangerous illicit alternatives.

AOC Takes a Stand Against Outdated Federal Laws Blocking Access to Cannabis and Psychedelics

Mar 30, 2026

Source:

Kyle Jaeger

Marijuana Moment

It is time for a serious conversation about the outdated rules that govern cannabis and psychedelics in this country. During a recent House subcommittee session, Representative Alexandria Ocasio-Cortez didn’t hold back, calling out the federal government for keeping substances like marijuana and LSD in the most restrictive legal category. This isn't just about politics; it is about the fact that our laws are currently ignoring a mountain of scientific evidence.

The core of the issue is Schedule I classification. By definition, these drugs are supposed to have no medical value and a high risk for addiction. However, as AOC and expert witnesses pointed out, the science says the exact opposite. We know these substances show incredible promise for treating conditions like PTSD and traumatic brain injuries. Keeping them locked away behind Schedule I doesn’t stop people from using them; it just stops scientists from researching how to use them safely and effectively.

For the average toker, this news is a reminder of why the push for rescheduling is so vital. When the government plays "whack-a-mole" by banning substances, it often pushes users toward more dangerous, unregulated alternatives in the illicit market. AOC argued that the current system actually fuels the overdose crisis rather than solving it, pointing to data where increased criminal penalties led to higher death rates.

The good news? The tide is turning. While the bureaucracy is moving slowly, the FDA has already acknowledged the potential of these compounds. We are currently in a waiting game for the Department of Justice to finalize the move of cannabis to Schedule III. This shift would be a massive win for the community, finally aligning federal law with the reality of medical use. It would mean better research, safer products, and a move away from the failed tactics of the past. Until then, keep an eye on these legislative updates—they are the roadmap to a more accessible and science-based future for all enthusiasts.

Recent Reviews

bottom of page